Open Orphan’s hVIVO article features in the Journal for Clinical Studies

Open Orphan plc (LON:ORPH), a rapidly growing specialist pharmaceutical services CRO and a world leader in vaccine and antiviral testing using human challenge clinical trials, has announced that an article has been written and published in the Journal for Clinical Studies. The article, entitled “Hot Topics – Vaccine Solutions for Tropical Diseases” is written by Adrian Wildfire, Director of Scientific and Business Strategy and Bruno Speder, VP of Regulatory Affairs and Consultancy Services at hVIVO, a subsidiary of Open Orphan plc.

The article explores the issue of vaccine development for tropical diseases for low and middle income countries and the barriers to effective treatments. In the article, hVIVO discuss how challenge study models can be used in the development of vaccines for tropical diseases. They further discuss the importance of Chemistry, Manufacturing & Control (CMC) development in relation to storage conditions, stress tests for tropical regions and the importance of non-clinical development.

The full article can be found here https://hvivo.com/hot-topics-vaccine-solutions-for-tropical-diseases/

Click to view all articles for the EPIC: ORPH
Or click to view the full company profile:
Open Orphan plc

Open Orphan’s hVIVO secures £7.2m contract with existing top 5 global pharmaceutical company

14th June 2022

Open Orphan plc (LON:ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced that hVIVO, a subsidiary of Open Orphan, has signed

Open Orphan swings to profit for the first time after ‘milestone year’ for the firm

13th June 2022

Revenue at the pharmaceutical services company increased almost 80 per cent last year after it secured a number of large contracts Open Orphan, the Dublin-listed pharmaceutical services company led by Cathal Friel, became profitable in 2021

Open Orphan Investor Presentation – 2021 a good year, 2022 will be a great year

10th June 2022

Open Orphan plc (LON:ORPH) Chief Executive Officer Yamin ‘Mo’ Khan talks through the FY2021 Financial Results and the outlook for 2022. Mo covers topics:The Vision,The Numbers,Overview,Key Strategic Value Adding Initiatives,Summary Financial Highlights,Attractive Market Dynamics,Growth of Vaccines &

Open Orphan appoints Martin Gouldstone as an Independent Non-Executive Director

8th June 2022

Monkeypox: The Lowdown

7th June 2022

An ongoing outbreak of monkeypox was confirmed on 6 May 2022, beginning with a British resident who, after travelling to Nigeria, presented symptoms consistent with monkeypox on 29 April 2022. The resident returned to the United

Open Orphan report record revenues and EBITDA-profitability and significant operational progress

7th June 2022

Open Orphan plc (LON:ORPH), a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced its audited final results for the 12

Open Orphan’s hVIVO signs a £14.7m influenza contract

1st June 2022

How to stop the spread of germs

31st May 2022

Flu season often wreaks havoc on workplaces, schools and communal living areas. It’s all too easy for germs to spread across surfaces and between people, swiftly infecting everyone within reach. It’s important to do what you

Open Orphan due diligence completed by Liberum Capital

26th May 2022

Open Orphan plc (LON:ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has today announced that further to the appointment of Liberum

Can elderberries help to fight the flu?

24th May 2022

Elderberries have long been in the limelight when it comes to their health-boosting properties. In fact, Healthline declared them to be “one of the most commonly used medicinal plants in the world”. Now, researchers think they may have

Open Orphan to publish full year results on 7 June 2022

24th May 2022

Open Orphan’s hVIVO wins a £7.3m influenza human challenge study

18th May 2022

The History of Flu

17th May 2022

Flu & Influenza The history of the flu dates to as far as humankind. Familiar symptoms of the flu were first recorded around 400BC by Hippocrates, a Turkish seasonal winter to spring respiratory ailment that resulted

The lowdown on hay fever

13th May 2022

Allergic rhinitis or, as it is commonly known, hay fever, is a reaction to allergens in the air. Most commonly this is a reaction to the pollen count, but can also be to dust, mould or

Open Orphan key considerations document for developing and manufacturing challenge agents published

12th May 2022

Open Orphan plc (LON:ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has noted a key considerations document for developing and manufacturing

Be sure to check our sister interview main ratings news website